Press Release|Articles|January 7, 2025
Camber Pharmaceuticals Announces Addition of Bortezomib for Injection
Listen
0:00 / 0:00
Key Takeaways
- Bortezomib for Injection is a proteasome inhibitor for treating multiple myeloma and mantle cell lymphoma in adults.
- The medication is available in a 3.5 mg strength, packaged in a single-dose vial.
Bortezomib for Injection is a proteasome inhibitor indicated for treatment of adult patients with multiple myeloma and treatment of adult patients with mantle cell lymphoma.
Advertisement
Camber Pharmaceuticals is excited to announce the addition of Bortezomib for Injection.
Bortezomib for Injection is a proteasome inhibitor indicated for:
- treatment of adult patients with multiple myeloma
- treatment of adult patients with mantle cell lymphoma
Bortezomib for Injection is available in 3.5 mg strength, packaged in a single-dose vial.
To find out more information on Bortezomib for Injection please visit:
Advertisement
Advertisement
Advertisement
Trending on Pharmacy Times
1
CKD Outcome Set Elevates Patient-Reported Measures
2
FDA Expands Accelerated Approval of Sevabertinib to First-Line HER2-Mutant NSCLC
3
In-Hospital Dapagliflozin Speeds Decongestion in Heart Failure
4
Tozorakimab Reduces COPD Exacerbations Across Eosinophil Levels in Phase 3 Trials
5